Systemic antifungal agents. Drug interactions of clinical significance.
about
Role of cytochrome P450 in drug interactionsInterventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infectionInterventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infectionAntifungal agents for common paediatric infectionsSafety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort studyIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsDipyridamole bioavailability in subjects with reduced gastric acidityThe effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individualsLack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram.Mortality and costs of acute renal failure associated with amphotericin B therapy.Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.Drug interactions of the newer oral antifungal agents.Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.Amphotericin B-induced nephrotoxicity: a review.Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.Rationale for combination antifungal therapy.Disseminated mycotic infection caused by Colletotrichum acutatum in a Kemp's ridley sea turtle (Lepidochelys kempi).Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Use of anti-infective agents during lactation, Part 3: Antivirals, antifungals, and urinary antiseptics.Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.The dog's role in the preclinical assessment of QT interval prolongation.Human pharmacogenomic variations and their implications for antifungal efficacy.Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.The in vitro antimicrobial activities of metabolites from lactobacillus strains on Candida species implicated in Candida vaginitis.Drug-drug interactions of antifungal agents and implications for patient care.Drug interactions during therapy with three major groups of antimicrobial agents.Role of posaconazole in the management of oropharyngeal and esophageal candidiasisAntimicrobial-associated QT interval prolongation: pointes of interest.Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.When primary antifungal therapy fails.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Azoles and antidepressants: a mini-review of the tolerability of co-administration.Antifungal research strategies aiming for new targets.QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Fungal infections in severe acute pancreatitis.Current concepts in antifungal pharmacology.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches.
P2860
Q21245066-DBB0E1A7-2529-431D-921D-03E895A8DF32Q24234875-53DE807F-7C29-49AD-9492-5D916EB10272Q24234997-25ED4805-A9DC-4945-96EB-592E46371759Q24656835-CE3B40DE-4128-48C1-B59E-D1597331FFE9Q24811445-9D68AB9B-9E8C-4A48-82C8-73B97C09933AQ26744049-6559459F-4EDD-4E36-AE96-923C0F0D56E9Q28177095-B9CFA013-1DF4-4E45-ADD8-E3F2A38886F9Q28367578-89F727BA-D770-48A3-9465-21209E0D6D81Q32049831-1412CA0C-1126-4730-94DE-45BAFD8AEC7EQ32068576-54AC2DA3-E8C4-46DA-B070-4FBE12425785Q33277939-423F0A3D-2EE7-401B-B456-118C8254A9FCQ33871614-831339E7-C41C-4C76-B37F-A01C25B626CDQ33979288-096E7844-667E-413D-8321-08B38D86DCADQ34128655-7008FB99-5DC6-484F-8E67-AE95A7BD7860Q34186776-19CDA45C-32BD-4EBB-A22D-133624A0A10CQ34335236-338C91FE-C987-48FE-AF59-800F9FFA0CD7Q34438709-28174D8A-08DD-4C3B-BA14-2B39B5DB300AQ34532546-163109AC-7C4D-457D-840B-7330379A562EQ34533723-A3C8CDCA-AC44-4DAC-8601-C987D4872BB3Q34563883-028DA895-A2C6-4CE6-A148-9C83521CA7B2Q35070458-FB805A92-FC33-435B-BE54-926D33D720A0Q35070838-7AADA64D-7C9C-4286-A7B0-813FDCB869EFQ35863175-5B13C6A3-01C6-46CD-BF98-CAC025294057Q35895788-EEDB66FB-3D7F-4EE1-AD4D-2FA95A0129CCQ36283721-849CA7E8-28EC-442A-B43C-927A94F2937CQ36429699-56ED2825-0C8C-43B4-89EC-18B6A58098B8Q36642964-4A630C82-A151-412D-B528-7DF3C1F70148Q36655034-E3AC7F40-4CF6-401F-96BE-B420D6AEA88AQ36662912-BFA6D00E-7A91-4822-AC4E-683A6179206AQ36792760-274BB14C-2E94-4B96-8523-80E7B03B0755Q37141191-3CE1789B-81E4-49A7-A11B-E03D4DEB7C60Q37157893-27BD76EB-259C-4096-97E4-DC1B76815744Q37389855-C8097674-2BFD-41F7-81F1-C38515F3CA6DQ37588637-0D5E4C36-8FEC-434F-A52B-3BD51B8F813CQ37727223-6841406D-B39F-4481-9E11-D673343B897EQ37836994-2A07373C-C95F-4CF7-9011-00247CE1A914Q37908856-3C5AA39C-891A-4B21-A8D3-06B1F1E53F05Q38284468-BACE005D-8E99-4E07-A35E-9CEB815B7DF5Q38681635-76835968-216C-435E-A5AC-5A954D524544Q38696236-FB75AE40-2C5A-4C3A-BEB1-09E2D08EBD45
P2860
Systemic antifungal agents. Drug interactions of clinical significance.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Systemic antifungal agents. Drug interactions of clinical significance.
@en
type
label
Systemic antifungal agents. Drug interactions of clinical significance.
@en
prefLabel
Systemic antifungal agents. Drug interactions of clinical significance.
@en
P2093
P1433
P1476
Systemic antifungal agents. Drug interactions of clinical significance.
@en
P2093
E Albengres
H Le Louët
J P Tillement
P356
10.2165/00002018-199818020-00001
P577
1998-02-01T00:00:00Z
P6179
1052548877